NasdaqGS:TXGLife Sciences
How ARK’s TXG Selloff and Cautious 2026 Outlook Will Impact 10x Genomics (TXG) Investors
In recent days, 10x Genomics has come under pressure as Cathie Wood’s ARK Invest sold more than 473,000 shares, prompting wider concerns among investors already uneasy about the company’s muted 2026 revenue growth guidance.
At the same time, 10x Genomics’ technology featured in PerturbAI’s release of a massive in vivo CRISPR brain atlas, highlighting the company’s tools as core infrastructure for cutting-edge AI-driven genomics research.
Next, we’ll examine how ARK Invest’s large share sale...